Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model

Area of Science:

• Oncology
• Bone Metabolism
• Cell Signaling

Background:

• DNA damage response is crucial for tumor growth but its role in bone metabolism is unclear.
• Mammary tumors often metastasize to bone, leading to pathological fractures.
• Understanding the interplay between tumor cell signaling and bone remodeling is essential.

Purpose of the Study:

• To investigate the role of Chk1 signaling in mammary tumor cell behavior and bone metabolism.
• To evaluate the therapeutic potential of Chk1 inhibitors in a bone metastasis mouse model.
• To elucidate the molecular mechanisms underlying Chk1 inhibition's effects on tumor cells and bone.

Main Methods:

• Selective Chk1 inhibitors were used to treat mammary tumor cells in vitro.
• Effects on osteoblast and osteoclast development were assessed.
• A mouse model of bone metastasis was utilized to evaluate Chk1 inhibitor efficacy on bone quality and osteolytic lesions.
• RNA-sequencing was performed to analyze gene expression changes.

Main Results:

• Chk1 inhibitors blocked mammary tumor cell proliferation, survival, and migration in vitro.
• Inhibitors suppressed osteoclast development by downregulating NFATc1.
• In vivo, Chk1 inhibition reduced osteolytic lesions and preserved bone mechanical strength in a mouse model of bone metastasis.
• Gene expression analysis revealed modulation of eukaryotic translation initiation factor 2 alpha, endoplasmic reticulum stress, S100 proteins, and bone remodeling genes.

Conclusions:

• Targeting Chk1 signaling is a promising strategy to simultaneously suppress tumor growth and migration while protecting bone from metastatic degradation.
• Chk1 inhibition offers a potential therapeutic approach for managing bone complications associated with mammary tumors.
• The findings highlight the intricate link between DNA damage response pathways and bone remodeling in the context of cancer metastasis.